Unlocking the Potential of Membrane Progesterone P4 Receptor Delta (PAQR6) as a Drug Target

Target Name: PAQR6

NCBI ID: G79957

PAQR6

Unlocking the Potential of Membrane Progesterone P4 Receptor Delta (PAQR6) as a Drug Target

Membrane progesterone P4 receptor delta (PAQR6) is a G protein-coupled receptor located on the membrane of cells, which plays a crucial role in various physiological processes. The PAQR6 receptor is involved in the regulation of various signaling pathways, including fetal development, tissue repair, and stress responses. It has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. As a result, targeting the PAQR6 receptor has become an attractive research topic in recent years.

In this article, we will discuss the PAQR6 receptor, its function, its potential as a drug target, and the current research in this field.

Function and Significance of PAQR6 Receptor

The PAQR6 receptor is a G protein-coupled receptor that is expressed in various tissues and cells, including the brain, pancreas, and uterus. It is involved in the regulation of various signaling pathways, including cell proliferation, differentiation, and survival. The PAQR6 receptor is activated by membrane progesterone P4 (P4), which is a natural hormone produced by the placenta.

The PAQR6 receptor plays a crucial role in fetal development, as it is involved in the regulation of pregnancy outcomes. Studies have shown that changes in the expression of PAQR6 can affect the risk of various pregnancy complications, including preterm delivery, low birth weight, and chromosomal abnormalities.

In addition to its role in fetal development, the PAQR6 receptor is also involved in the regulation of tissue repair and stress responses. It has been shown to play a role in the regulation of inflammation, pain perception, and stress responses.

Potential as a Drug Target

The PAQR6 receptor is a potential drug target due to its involvement in various diseases. Several studies have shown that targeting the PAQR6 receptor can lead to the development of new treatments for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

For example, several studies have shown that targeting the PAQR6 receptor can lead to the inhibition of cancer cell proliferation. This is because the PAQR6 receptor is involved in the regulation of cell growth and survival, and inhibiting its function can lead to the inhibition of cancer cell growth.

In addition to its potential as a cancer treatment, the PAQR6 receptor is also a potential target for neurodegenerative disorders. Studies have shown that changes in the expression of PAQR6 can affect the progression of neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. Therefore, targeting the PAQR6 receptor has the potential to lead to new treatments for neurodegenerative disorders.

Current Research in the Field

Several studies have investigated the PAQR6 receptor and its potential as a drug target. These studies have led to a better understanding of the PAQR6 receptor's function and its involvement in various diseases.

One of the most significant findings of recent studies is the identification of a new ligand for the PAQR6 receptor, known as P4-10. P4-10 is a synthetic compound that can inhibit the activity of the PAQR6 receptor and has been shown to have potential as a drug treatment for various diseases.

Another significant finding of recent studies is the identification of a new target gene for the PAQR6 receptor, known as gene ID 1313222. This gene has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis (programmed cell death), and inflammation.

Conclusion

In conclusion, the PAQR6 receptor is a G protein-coupled receptor that is involved in various signaling pathways

Protein Name: Progestin And AdipoQ Receptor Family Member 6

Functions: Plasma membrane progesterone (P4) receptor coupled to G proteins (PubMed:23763432, PubMed:23161870). Seems to act through a G(s) mediated pathway (PubMed:23161870). Involved in neurosteroid inhibition of apoptosis (PubMed:23161870). May be involved in regulating rapid P4 signaling in the nervous system (PubMed:23763432). Also binds dehydroepiandrosterone (DHEA), pregnanolone, pregnenolone and allopregnanolone (PubMed:23763432, PubMed:23161870)

The "PAQR6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAQR6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets